The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).
 
Jonathan Wade Goldman
Honoraria - Clovis Oncology; Genentech
Research Funding - ArQule; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Synta
 
Jean-Charles Soria
Honoraria - AstraZeneca/MedImmune; Merus; MSD Oncology; Pfizer; Roche/Genentech; Symphony Evolution
 
Heather A. Wakelee
Honoraria - ACEA Biosciences; Biocon; Helsinn Therapeutics; Peregrine Pharmaceuticals; Pfizer
Consulting or Advisory Role - ACEA Biosciences; Helsinn Therapeutics; Peregrine Pharmaceuticals; Pfizer
Research Funding - Agennix (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - ACEA Biosciences; Clovis Oncology; Novartis; Pfizer
 
D. Ross Camidge
Honoraria - Clovis Oncology
 
Shirish M. Gadgeel
Consulting or Advisory Role - Biodesix; Boehringer Ingelheim; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - Genentech/Roche
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst)
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca
Research Funding - Astellas Pharma; AstraZeneca; Clovis Oncology; Esanex; Incyte; Pfizer
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; Boehringer Ingelheim
Research Funding - Adaptimmune; ARIAD; Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Eisai; Gilead Sciences; GlaxoSmithKline; Novartis; Pfizer; Pfizer; Xcovery
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Amgen; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Janssen; Lilly; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); ITO - EN (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Maurice Perol
Honoraria - Clovis Oncology
Consulting or Advisory Role - Clovis Oncology
 
Sai-Hong Ignatius Ou
Honoraria - Pfizer; Roche Pharma AG
Consulting or Advisory Role - Pfizer; Roche/Genentech
Speakers' Bureau - Boehringer Ingelheim; Genentech
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Shannon L. Matheny
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Darrin Despain
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Jeffrey D. Isaacson
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Sergey Yurasov
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Lindsey Rolfe
Employment - Clovis Oncology
Leadership - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Lecia V. Sequist
Consulting or Advisory Role - ARIAD; AstraZeneca; Clovis Oncology; Merrimack; Novartis; Taiho Pharmaceutical
Research Funding - ArQule (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)